Turning Point Therapeutics (Nasdaq:TPTX) - Prezzo delle azioni, notizie e analisi

TPTX Panoramica delle azioni

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. Maggiori dettagli

TPTX analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 73.92% all'anno

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Non ha entrate significative ( $1M )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Turning Point Therapeutics, Inc. Concorrenti

Chinook Therapeutics

NasdaqGS:KDNY

US$2.9b

ADMA Biologics

NasdaqGM:ADMA

US$5.1b

Alpine Immune Sciences

NasdaqGM:ALPN

US$4.5b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Turning Point Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$76.01
Massimo di 52 settimane	US$82.20
Minimo di 52 settimane	US$23.77
Beta	-0.19
1Variazione di 1 mese	1.58%
Variazione a 3 mesi	114.96%
Variazione di 1 anno	18.90%
3Variazione a 3 anni	45.39%
Variazione a 5 anni	n/a
Variazione dall'IPO	163.01%

Notizie e aggiornamenti recenti

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

Rendimenti per gli azionisti

	TPTX	US Biotechs	US Mercato
7D	1.3%	4.0%	2.0%
1Y	18.9%	18.0%	32.4%

Ritorno vs Industria: TPTX ha superato il US Biotechs che ha restituito 18 % nell'ultimo anno.

Rendimento vs Mercato: TPTX ha superato il mercato US che ha restituito 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is TPTX's price volatile compared to industry and market?
TPTX volatility
TPTX Average Weekly Movement	34.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di TPTX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di TPTX è aumentata da 20% a 34% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	267	Athena Countouriotis	www.tptherapeutics.com

Turning Point Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Turning Point Therapeutics con la sua capitalizzazione di mercato?
TPTX statistiche fondamentali
Capitalizzazione di mercato	US$3.81b
Guadagni(TTM)	-US$342.31m
Ricavi(TTM)	US$1.01m

3,776x

Rapporto P/S

-11.1x

Rapporto P/E

TPTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TPTX Conto economico (TTM)
Ricavi	US$1.01m
Costo del fatturato	US$0
Profitto lordo	US$1.01m
Altre spese	US$343.32m
Guadagni	-US$342.31m

Ultimi guadagni dichiarati

Jun 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-6.84
Margine lordo	100.00%
Margine di profitto netto	-33,959.03%
Rapporto debito/patrimonio netto	0%

Come si è comportato TPTX nel lungo periodo?

Vedi performance storica e confronto

TPTX Panoramica delle azioni

Premi

Analisi del rischio

Turning Point Therapeutics, Inc. Concorrenti

NasdaqGS:KDNY

US$2.9b

NasdaqGM:ADMA

US$5.1b

NasdaqGM:ALPN

US$4.5b

NasdaqCM:CPRX

US$2.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Recent updates

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index

Turning Point Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

Turning Point Therapeutics, Inc. Provides Operational and Clinical Update

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Executive VP & CFO recently sold US$89k worth of stock

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index

Price target decreased to US$79.50

Price target decreased to US$87.71

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Turning Point Therapeutics, Inc. (NasdaqGS:TPTX) for $3.8 billion.

Consensus forecasts updated

Turning Point Therapeutics, Inc. Announces Appointment of Steve Sabus as Chief Commercial Officer, Effective as of May 31, 2022

Price target decreased to US$105

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Turning Point Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Turning Point Therapeutics, Inc. Announces Positive Topline Results from the Registrational TRIDENT-1 Study Across All Four ROS1-Positive Advanced Non-Small Cell Lung Cancer Cohort

Turning Point Therapeutics, Inc. Appoints Brian Sun as Senior Vice President and General Counsel, Effective April 11, 2022

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Turning Point Therapeutics, Inc. Announces the Resignation of Siegfried Reich as Executive Vice President and Chief Scientific Officer

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to US$119

Turning Point Therapeutics, Inc. Announces Retirement of Annette North as Executive Vice President, General Counsel and Corporate Secretary, Effective March 4, 2022

President recently sold US$108k worth of stock

Turning Point Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for Combination of Elzovantinib and Aumolertinib in Egfr Mutant Met-Amplified Non-Small Cell Lung Cancer

Turning Point Therapeutics, Inc. Provides Updates and Anticipates 2022 Clinical and Discovery Pipeline Milestones

Turning Point Therapeutics, Inc. Announces Regulatory Updates for Its Lead Drug Candidate, Repotrectinib, ROS1/TRK Inhibitor, and for Elzovantinib (TPX-0022), Its Drug Candidate Targeting MET, CSF1R and SRC

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Price target decreased to US$134

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

Executive VP exercised options and sold US$630k worth of stock

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

Consensus revenue estimates increase to US$30.4m

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Executive VP & Chief Commercial Officer recently sold US$140k worth of stock

Chairman of the Board recently bought US$163k worth of stock

Turning Point Therapeutics, Inc. Grants FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Executive VP exercised options and sold US$900k worth of stock

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Senior VP of Finance & Administration and Principal Accounting Officer has left the company

Consensus forecasts updated

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Turning Point Therapeutics, Inc. Appoints Brian Baker as the Interim Principal Financial Officer

Turning Point Therapeutics, Inc. Announces Executive Changes, Effective March 31, 2021

Analysts update estimates

New 90-day low: US$103

Earnings beat expectations, revenue disappoints

Turning Point Therapeutics, Inc. Provides Operational and Clinical Updates

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

President exercised options and sold US$8.1m worth of stock

New 90-day high: US$140

Price target raised to US$160

Turning Point Therapeutics Reports Updated Interim Data from Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher